PMA supplement
P130021 S079: Evolut PRO+ TAV of the Evolut PRO+ System, Evolut PRO TAV of the Evolut PRO System, Evolut R TAV of the Evolut R System
FDA PMA supplement · 30-Day Notice · Medtronic, Inc.
Key facts
| Original PMA | P130021 |
|---|---|
| Supplement number | S079 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Evolut PRO+ TAV of the Evolut PRO+ System, Evolut PRO TAV of the Evolut PRO System, Evolut R TAV of the Evolut R System |
| Generic name | Aortic valve, prosthesis, percutaneously delivered |
| Applicant | Medtronic, Inc. |
| Product code | NPT |
| Received date | Jul 8, 2020 |
| Decision date | Jul 13, 2020 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: